Pharmacogenomics: current status and future perspectives

M Pirmohamed - Nature Reviews Genetics, 2023 - nature.com
Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

Pharmacogenomics in practice: A review and implementation guide

D Kabbani, R Akika, A Wahid, AK Daly… - Frontiers in …, 2023 - frontiersin.org
Considerable efforts have been exerted to implement Pharmacogenomics (PGx), the study
of interindividual variations in DNA sequence related to drug response, into routine clinical …

Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank

B Li, K Sangkuhl, R Whaley, M Woon, K Keat… - The American Journal of …, 2023 - cell.com
Pharmacogenomics (PGx) is an integral part of precision medicine and contributes to the
maximization of drug efficacy and reduction of adverse drug event risk. Accurate information …

Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx …

MI Koufaki, V Fragoulakis, X Díaz-Villamarín… - Human Genomics, 2023 - Springer
Background Cardiovascular diseases and especially Acute Coronary Syndrome (ACS)
constitute a major health issue impacting millions of patients worldwide. Being a leading …

Circulating biomarkers instead of genotyping to establish metabolizer phenotypes

R Tremmel, U Hofmann, M Haag… - Annual Review of …, 2024 - annualreviews.org
Pharmacogenomics (PGx) enables personalized treatment for the prediction of drug
response and to avoid adverse drug reactions. Currently, PGx mainly relies on the genetic …

Clinical implementation of preemptive pharmacogenomics in psychiatry

M Skokou, K Karamperis, MI Koufaki, EE Tsermpini… - …, 2024 - thelancet.com
Summary Background Pharmacogenomics (PGx) holds promise to revolutionize modern
healthcare. Although there are several prospective clinical studies in oncology and …

Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy

DL Hertz, DM Smith, SA Scott, JN Patel… - Clinical Pharmacology …, 2023 - Wiley Online Library
Fluoropyrimidine (FP) chemotherapy is associated with severe, life‐threatening toxicities,
particularly among patients who carry deleterious germline variants in the DPYD gene …

Development and Bioequivalence of 3D‐Printed Medication at the Point‐of‐Care: Bridging the Gap Toward Personalized Medicine

M Lyousoufi, I Lafeber, D Kweekel… - Clinical …, 2023 - Wiley Online Library
Personalized medicine is currently hampered by the lack of flexible drug formulations.
Especially for pediatric patients, manual compounding of personalized drug formulations by …

The case for precision medicine in the prevention, diagnosis, and treatment of cardiometabolic diseases in low-income and middle-income countries

S Misra, CA Aguilar-Salinas, T Chikowore… - The Lancet Diabetes & …, 2023 - thelancet.com
Cardiometabolic diseases are the leading preventable causes of death in most
geographies. The causes, clinical presentations, and pathogenesis of cardiometabolic …

Impact of pharmacogenomics in clinical practice

N Principi, K Petropulacos, S Esposito - Pharmaceuticals, 2023 - mdpi.com
Polymorphisms of genes encoding drug metabolizing enzymes and transporters can
significantly modify pharmacokinetics, and this can be associated with significant differences …